Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity.
Flaherty SE 3rd, Bezy O, Zheng W, Yan D, Li X, Jagarlapudi S, Albuquerque B, Esquejo RM, Peloquin M, Semache M, Mancini A, Kang L, Drujan D, Breitkopf SB, Griffin JD, Jean Beltran PM, Xue L, Stansfield J, Pashos E, Shakey Q, Pehmøller C, Monetti M, Birnbaum MJ, Fortin JP, Wu Z. Flaherty SE 3rd, et al. Among authors: birnbaum mj. Nat Commun. 2023 Jul 4;14(1):3953. doi: 10.1038/s41467-023-39597-w. Nat Commun. 2023. PMID: 37402735 Free PMC article.
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Saxena AR, Frias JP, Gorman DN, Lopez RN, Andrawis N, Tsamandouras N, Birnbaum MJ. Saxena AR, et al. Among authors: birnbaum mj. Diabetes Obes Metab. 2023 Oct;25(10):2805-2814. doi: 10.1111/dom.15168. Epub 2023 Jun 13. Diabetes Obes Metab. 2023. PMID: 37311722 Clinical Trial.
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ. Saxena AR, et al. Among authors: birnbaum mj. JAMA Netw Open. 2023 May 1;6(5):e2314493. doi: 10.1001/jamanetworkopen.2023.14493. JAMA Netw Open. 2023. PMID: 37213102 Free PMC article. Clinical Trial.
GLUT4 dynamic subcellular localization is controlled by AMP kinase activation as revealed by proximal proteome mapping in human muscle cells.
Ray A, Wen J, Yammine L, Culver J, Garren J, Xue L, Hales K, Xiang Q, Birnbaum MJ, Zhang BB, Monetti M, McGraw TE. Ray A, et al. Among authors: birnbaum mj. bioRxiv [Preprint]. 2023 Jun 7:2023.06.06.543897. doi: 10.1101/2023.06.06.543897. bioRxiv. 2023. Update in: J Cell Sci. 2023 Dec 1;136(23):jcs261454. doi: 10.1242/jcs.261454. PMID: 37333333 Free PMC article. Updated. Preprint.
Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop.
Garcia JM, Dunne RF, Santiago K, Martin L, Birnbaum MJ, Crawford J, Hendifar AE, Kochanczyk M, Moravek C, Piccinin D, Picozzi V, Roeland EJ, Selig WKD, Zimmers TA. Garcia JM, et al. Among authors: birnbaum mj. J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1418-1425. doi: 10.1002/jcsm.12910. Epub 2022 Feb 26. J Cachexia Sarcopenia Muscle. 2022. PMID: 35218313 Free PMC article. No abstract available.
Molecular aspects of fructose metabolism and metabolic disease.
Herman MA, Birnbaum MJ. Herman MA, et al. Among authors: birnbaum mj. Cell Metab. 2021 Dec 7;33(12):2329-2354. doi: 10.1016/j.cmet.2021.09.010. Epub 2021 Oct 6. Cell Metab. 2021. PMID: 34619074 Free PMC article. Review.
255 results